Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gematinib Combined With Lenvatinib in Advanced or Metastatic NSCLC With MET Overexpression
NCT07894367Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2026
- Primary completion
- Aug 2028
01
Overview
A Phase 2 trial of gumarontinib, lenvatinib in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
gumarontiniblenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07894367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07894367.